Cargando…

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision

Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Kelsey E., Lu, Karen H., Klimczak, Amber M., Mok, Samuel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836089/
https://www.ncbi.nlm.nih.gov/pubmed/29466291
http://dx.doi.org/10.3390/cancers10020057
_version_ 1783303911250067456
author Lewis, Kelsey E.
Lu, Karen H.
Klimczak, Amber M.
Mok, Samuel C.
author_facet Lewis, Kelsey E.
Lu, Karen H.
Klimczak, Amber M.
Mok, Samuel C.
author_sort Lewis, Kelsey E.
collection PubMed
description Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.
format Online
Article
Text
id pubmed-5836089
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58360892018-03-07 Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision Lewis, Kelsey E. Lu, Karen H. Klimczak, Amber M. Mok, Samuel C. Cancers (Basel) Review Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions. MDPI 2018-02-21 /pmc/articles/PMC5836089/ /pubmed/29466291 http://dx.doi.org/10.3390/cancers10020057 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lewis, Kelsey E.
Lu, Karen H.
Klimczak, Amber M.
Mok, Samuel C.
Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
title Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
title_full Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
title_fullStr Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
title_full_unstemmed Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
title_short Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
title_sort recommendations and choices for brca mutation carriers at risk for ovarian cancer: a complicated decision
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836089/
https://www.ncbi.nlm.nih.gov/pubmed/29466291
http://dx.doi.org/10.3390/cancers10020057
work_keys_str_mv AT lewiskelseye recommendationsandchoicesforbrcamutationcarriersatriskforovariancanceracomplicateddecision
AT lukarenh recommendationsandchoicesforbrcamutationcarriersatriskforovariancanceracomplicateddecision
AT klimczakamberm recommendationsandchoicesforbrcamutationcarriersatriskforovariancanceracomplicateddecision
AT moksamuelc recommendationsandchoicesforbrcamutationcarriersatriskforovariancanceracomplicateddecision